{"ticker": {"uuid": "e00e9f1a-0977-4bc6-adff-a31cefbf53e8", "symbol": "SCNI", "name": "Scinai Immunotherapeutics Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Scinai Immunotherapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxNM1oxazlvUUl4bkozRV8yUXVjX1lVcEwtLXFpRmdrZnRhU3U1QWZid0drdVZ0RkEtV0VNQy14Rmp3U1B1OHJ4VXpUZzg3M05vTnp3N3kxNTVLaXVfTkd3SWlpZS1kTnhNVTVscC1iREVnR3MtNzZrWXZta0QzWTFFSU1vZUZBVjJ2VWZ0NjluVTItRVY1WDVRUnJsOGZreUpKREFQOUxmQnpMeGR4allRTFd0aklySkpIeUpKbDVqQXVRVUFqR21vUUNvSmt1OUVmU1hycjBBbHl2X0ZxMlRiQ3lhMnFOemRNTlE2QWJmMm1VUEZ4NW9SMnpEdnk0NlpSd2FGVHA3b21NQ1A5aEVnMFQ4MWE5Y0tkM1NUbW56enZRMzBRVDh0OFFubDVyS3ZwVE5BUjJxZEhvd0JRWDMtclBxdFNQUlMt?oc=5", "source_name": "Moomoo", "published_at": "2026-07-18T07:06:54+00:00", "published_display": "18 Jul 2026 07:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LCK JNK 1 LLC takes 6.33% stake in Scinai Immunotherapeutics (SCNI)", "summary": "LCK JNK 1 LLC has reported a 6.33% passive stake in Scinai Immunotherapeutics (SCNI), holding 317,366 American Depository Shares (ADS). Each ADS represents 4,000 ordinary shares. The filing indicates LCK JNK 1 LLC holds sole voting and dispositive power over these shares, as deta", "url": "https://www.stocktitan.net/sec-filings/SCNI/schedule-13g-a-scinai-immunotherapeutics-ltd-amended-passive-investme-775947b5d66c.html", "source_name": "Stock Titan", "published_at": "2026-07-09T13:35:29", "published_display": "09 Jul 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI - Scinai Immunotherapeutics Ltd ADR Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Scinai Immunotherapeutics Ltd ADR (SCNI), along with a comprehensive overview of its financial performance, key metrics, and market data. It covers various aspects such as market capitalization, income, sales, per-share ", "url": "https://finviz.com/stock?t=SCNI&ty=lf&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-05T07:40:38", "published_display": "05 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI - Scinai Immunotherapeutics Ltd ADR Options", "summary": "This article provides detailed financial data and performance metrics for Scinai Immunotherapeutics Ltd ADR (SCNI). It includes key financial ratios, stock performance over various periods, insider ownership, institutional ownership, and volume data. The stock closed at $0.2408, ", "url": "https://finviz.com/stock?t=SCNI&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T19:42:02", "published_display": "04 Jul 2026 19:42", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Surges 7.68% as Speculative Interest Intensifies - Andrews Pitchfork", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPQlpHdFF2ZEdqX1hEdnRDS2lXMXAwSmttYnJQV2MycVNjMzIzSkZFNkc1bFg1Snp5MVRTcklpZmRxR3l4ajBNRkdYS1hlcnUzMWotUV8tU1lLbjI0aFZCUGNsb3F5WTR6MzFqZnpzWmRfNXdydEpUWHBJTzFkcmkxQ01YZ29uY29iblVBQmNuS2VQNFlvQkhHY05MdE9rSWxCZzE4Y0ZDMlVsZ0JuT3hqdDN4U3BZdkN1MGhHQ2Z3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T22:44:17+00:00", "published_display": "01 Jul 2026 22:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daniel Stone, RK Stone Miami adjust SCNI holdings (SCNI) after warrant exercises", "summary": "Daniel Stone and RK Stone Miami, LLC have updated their holdings in Scinai Immunotherapeutics Ltd. (SCNI) following warrant exercises, as reported in an amended SCHEDULE 13G/A filing. The filing details increased sole voting power for both parties, with RK Stone Miami, LLC exerci", "url": "https://www.stocktitan.net/sec-filings/SCNI/schedule-13g-a-scinai-immunotherapeutics-ltd-amended-passive-investme-6b721a9e5942.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:40:06", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI)", "summary": "This article provides an overview of Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), including its stock market information, financial data, and analyst estimates. It highlights that users can explore reported financial data, compare actual results with estimates, and visualize fin", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:17", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Scinai Immunotherapeutics Ltd. \u2013 NASDAQ:SCNI", "summary": "This article provides the \"Price to sales forward\" financial metric for Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI). It appears to be a stub or an incomplete data entry, as the actual value and change for the metric are not displayed. The page lists various navigation and copyr", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:17", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Scinai Immunotherapeutics Ltd. \u2013 NASDAQ:SCNI", "summary": "This article provides financial information for Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data display page from TradingView, indicating no available trades and offering various market d", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:40:16", "published_display": "25 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Scinai Immunotherapeutics Ltd (SCNI), noting its current valuation score is 7.47, ranking it 215 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -0.08, which is significantly belo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T02:09:20", "published_display": "23 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Drops 9.5% as Shares Approach Key Support at $0.28 - Short Term Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQWG1QbVZoTVBVeENIeThVSWp2bVp6MHZIREhuY2xNY25CTG40Q3kza0haeFhSLWtlcktiU2lRb0JCclMxdWRXNGo2dFRTNkhZLWtrZmZRSTNsU1pWYUxzMEpiMVNGT2tDX3NtczJyeWg2SEVZajBaM25GV2lTR3gzYXUxS0JyWmJPal9Fa3FwWEI2UC04WS1IUy0weDQzeDFJTHBjS3hRRkxub0JwSXZtQnhXVVdfSTFpV0IxdUd3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd", "summary": "This article provides a company overview for Scinai Immunotherapeutics Ltd (SCNI), including its stock performance and market capitalization. It highlights that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/revenue", "source_name": "TradingKey", "published_at": "2026-06-20T17:40:06", "published_display": "20 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Scinai Immunotherapeutics Ltd (SCNI), outlining its major shareholders and institutional holdings. It provides a breakdown of individual and corporate shareholders, their respective proportions, and historical data on institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/ownership", "source_name": "TradingKey", "published_at": "2026-06-20T16:40:06", "published_display": "20 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Scinai Immunotherapeutics Ltd's (SCNI) dividend history and stock split events. It notes that SCNI has distributed $0.00 in dividends over the past five years and lists several merger-type stock splits that occurred on May 6, 2024, and Novembe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-20T15:40:06", "published_display": "20 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Shareholders Approve Board Slate, Equity Expansion and Executive Awards", "summary": "Scinai Immunotherapeutics shareholders approved the re-election of directors, an amendment to increase authorized ordinary shares for capital raising flexibility, and several executive and board compensation items. These approvals included amendments to CEO Amir Reichman's employ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SCNI/pressreleases/2532223/scinai-immunotherapeutics-shareholders-approve-board-slate-equity-expansion-and-executive-awards/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T15:10:35", "published_display": "20 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) CEO receives 400,000,000-share RSU award", "summary": "Scinai Immunotherapeutics Ltd. CEO Amir Reichman was granted 400,000,000 Ordinary Shares as Restricted Share Units (RSUs) on June 16, 2026, at a price of $0.00 per share. These RSUs will vest in three equal annual installments, contingent upon his continued service. Following thi", "url": "https://www.stocktitan.net/sec-filings/SCNI/form-4-scinai-immunotherapeutics-ltd-insider-trading-activity-c89ae117de41.html", "source_name": "Stock Titan", "published_at": "2026-06-18T18:40:56", "published_display": "18 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) director awarded 120M Ordinary Share RSUs", "summary": "Scinai Immunotherapeutics director Mark Germain was awarded 120 million Ordinary Shares as Restricted Share Units (RSUs) on June 16, 2026. These RSUs were granted at no cash cost and will vest in three equal annual installments, contingent on his continued service. Following this", "url": "https://www.stocktitan.net/sec-filings/SCNI/form-4-scinai-immunotherapeutics-ltd-insider-trading-activity-e9b1c9269701.html", "source_name": "Stock Titan", "published_at": "2026-06-18T18:40:56", "published_display": "18 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Scinai Immunotherapeutics Ltd (SCNI), providing a financial score of 6.87, which ranks it 197th in the Biotechnology & Medical Research industry. It notes the company's stable financial status and high operating efficiency. However, t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:56", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Scinai Immunotherapeutics Ltd (SCNI), noting that no earnings forecast score is currently available for the company. It highlights that the biotechnology and medical research industry average is 8.13 for this score. The article also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:56", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Scinai Immunotherapeutics Ltd (SCNI), highlighting its current score and changes. It lists top institutional shareholders and their recent activity, including shares held and percentage change. The data is cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:56", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) investors approve board, share hike, RSU grants", "summary": "Scinai Immunotherapeutics shareholders approved all proposals at their Annual Meeting on June 16, 2026. Key approvals included the re-election of directors, an amendment to increase the number of authorized ordinary shares, and several compensation-related items for CEO Amir Reic", "url": "https://www.stocktitan.net/sec-filings/SCNI/6-k-scinai-immunotherapeutics-ltd-current-report-foreign-issuer-a15e4672eab1.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:10:51", "published_display": "17 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI SEC Filings - Scinai Immunotherapeutics Ltd. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Scinai Immunotherapeutics Ltd. (SCNI) SEC filings, including annual, quarterly, and current reports, along with insider trading forms. It highlights recent filings such as the denial of a Euro 12M grant for PC111 development, a new ", "url": "https://www.stocktitan.net/sec-filings/SCNI/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T23:40:56", "published_display": "16 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai (NASDAQ: SCNI) posts Q1 2026 profit on Recipharm Israel gain", "summary": "Scinai Immunotherapeutics (NASDAQ: SCNI) reported a net income of $3.6 million for Q1 2026, primarily driven by a $6.2 million non-cash bargain purchase gain from its acquisition of Recipharm Israel. Despite an operating loss of $2.5 million, the acquisition significantly strengt", "url": "https://www.stocktitan.net/sec-filings/SCNI/6-k-scinai-immunotherapeutics-ltd-current-report-foreign-issuer-00dbf42694e9.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:34", "published_display": "15 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives", "summary": "Scinai Immunotherapeutics Ltd. reported its financial results for the first quarter of 2026, highlighting the acquisition of Recipharm Israel which expanded its CDMO platform and manufacturing capabilities. The company also provided a corporate update, detailing advancements in n", "url": "https://www.prnewswire.com/il/news-releases/scinai-reports-first-quarter-2026-financial-results-and-provides-corporate-update-highlighting-expansion-of-cdmo-platform-and-advancement-of-strategic-growth-initiatives-302796684.html", "source_name": "PR Newswire", "published_at": "2026-06-14T19:09:41", "published_display": "14 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd. (SCNI) stock price, news, quote and history", "summary": "Scinai Immunotherapeutics Ltd. (SCNI) is a biopharmaceutical company specializing in the research and development of immune-mediated and inflammatory disease treatments, including an IL-17 NanoAb platform and PC111 for conditions like pemphigus. The company also provides contract", "url": "https://au.finance.yahoo.com/quote/SCNI/", "source_name": "Market source", "published_at": "2026-06-12T10:09:40", "published_display": "12 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]", "summary": "This document is classified as a 6-K report, which is a filing submitted by foreign private issuers to the U.S. Securities and Exchange Commission (SEC) under Rules 13a-16 and 15d-16. The content of the report is simply \"Document,\" indicating it is a placeholder or an external do", "url": "https://www.moomoo.com/news/notice/307487099/scinai-immunotherapeutics-6-k-report-of-foreign-private-issuer-rules", "source_name": "Moomoo", "published_at": "2026-06-12T09:10:26", "published_display": "12 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives", "summary": "Scinai reported its first quarter 2026 financial results, emphasizing the expansion of its CDMO platform and the advancement of strategic growth initiatives. The report likely details the company's financial performance and operational developments during the quarter, reflecting ", "url": "https://www.moomoo.com/news/post/71330980/press-release-scinai-reports-first-quarter-2026-financial-results-and", "source_name": "Moomoo", "published_at": "2026-06-11T10:09:40", "published_display": "11 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai reports Q1 2026 net income of $3.6 million", "summary": "Scinai Immunotherapeutics Ltd reported a net income of $3.6 million for Q1 2026, a significant turnaround from a $1.6 million net loss in the previous year. This improvement was largely due to a $6.2 million bargain purchase gain from the acquisition of Recipharm Israel, which al", "url": "https://scanx.trade/stock-market-news/companies/scinai-reports-q1-2026-net-income-of-3-6-million/42639352", "source_name": "scanx.trade", "published_at": "2026-06-10T12:39:22", "published_display": "10 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics reports Q1 2026 financial results", "summary": "Scinai Immunotherapeutics (NASDAQ:SCNI) reported a net profit of $3.6 million for Q1 2026, a significant turnaround from a loss in the prior year, primarily due to a $6.2 million non-cash bargain purchase gain from its Recipharm Israel acquisition. Despite this, total revenues de", "url": "https://grafa.com/en/news/united-states/scni-earnings-q1-2026", "source_name": "grafa.com", "published_at": "2026-06-10T12:10:00", "published_display": "10 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Q4 2023 Earnings: EPS Surpasses Estimates Amid Continued Development Progress - EPS Surprise History", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQaFRBaVZ1eGZ4ay1BRlNlOEdiNTdUWFROSkRKZWFBVGRPSkxRRW96Vi1Cb3RkRngtblpGOWdvWFlMWVRCU2pldEpIbHRwVmIwdUpqTXpFUXE0bEdrVDBkMndCNnpYVGlMeGdjclROUzFKVW0xSmVYX2pQSVBWWUN6bW9KYkZGWHdHQmxxWi1yZVIzcXE4OFZSNDVUby1VQ0ZSVjdyVlJ5cVVaVFQ2U2ljaGhrcjZrZWVUTDl5QnJ2WVR3Qlc2RU14RGZINm92WlhtM0NFOVpDemlDaUI4dmo3cUlydw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Declines 7.25%, Eyes Key Support at $0.43 - Ichimoku Kumo Twist", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNMUJ6bnlwU3lhaXQ5eFhMTGdJRHp2TWV5bmE1a2xoMzh6SU1TanlFZHlMOThoNXI2TVVzNVlZczYzVG1ETnBEdHI2MkszTkp4d0gzRkxyTXRkd3MxczBNeEU0MWdVQUIybE1mVnQxUzQ5QTgwUDRxaUx5TnRWcGF0cTRzS3dDWlNjZ085U29JMFQzdlU1ZjcxVHM5a0llRGVpZmZ3TGZHVG1hUUJZTFhDM1hR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scinai-biopharma-services-appoints-eilon-110000686.html", "source_name": "PR Newswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scinai-immunotherapeutics-lead-strategic-roundtable-113000591.html", "source_name": "PR Newswire", "published_at": "2026-05-15T11:30:00+00:00", "published_display": "15 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Scinai raises $2.61M to expand drug manufacturing, fund programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPbVBUOW0wajJNQ1d0YW85VUNKaTNxYVNkeDFac0czWG9FSTdqcUdTVy04SksyeXhrQjNuMVZjXzJlWUpHOEVkQkxYclZLNWRUcGVaRFVDUmxIcGM4U0l5TW1FUzUtQ0F3dnpKcFg3bW13aE1ReklGX0t0X2tXRHlaV2lVamlZT1VPTzVOaGx1cms2WU02dVNnb0huNzhTRmVaZHhqLWM4aTg5RDREX0VGellyUjdEOUk0Zkhpc1B3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxObm9GSzhISjhoN0FGb2dIOURDTDF2Z1Z0UEFpVTZMU29qRzVicVdRNm1yV2tmSl9DOTVveWhETnhIcDZJTzZ6WjhHZHp3S1ZaYXBiTWttT0pLOTRGbDFGNjhmXzlaanhCMEl0NDVuSFlLbGw2OUc1R0U2WWcwTEg5LVljUS0tU0dCTUdGcC1EdzY1MDNRbzVzdFd3NjlqX243QkRmQXI5SThKemxfVG9rb3BkWmFHOG9Kd0VtWXdrT2RpZ3dWNlFzNWVmb3Y?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics jumps on $2.61M private placement financing | SCNI Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUVhMTlMtd1llNEhJSUdPSWs1WF9CTDNBdGhLNW9oZ2hweTRvREVWTFg5Vkp4TU1oZ0dSQkQ3dm1uYU1CN09JTkE5WXRzT01Jc091OWZ1SWFLSkRIcndtVGJpSHhIempPYVMzUHRuVnJpZ2dtVlhzOXprQXNUYTI2ZHAxSnRPdXhBdDRFQU1neWwwZjB1Y3N1MkRqTUttM0Y3TGNNWQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxOMXlxdUZTTHRmeEQ2TmIwSUtIRzRwVHpaWVdiTFBsSmxrV3hybEh0dTZ5VXNWUm9jenVnZkh1dVF4UGhZbWI5UmFhQmtlN2ZXNFd4VVByZ1BmM3RqWjlFeGdGeUtWNFdia0Qzei1qZXlVT3d5eko1bFcxRWdOeVd0X1ctZ0p6ZUpJTzIwbjFQa0hOeXZWWXJtZGp5TU5hZm9zX3VvSi1YSmR4cXIxOTdVaUZwU3hCd05lV01Wc2tkZHNMYVhOTkhQcjFmSzZGOHdOUEdNTGE2YU1WWnozcmF1QjRuVVhid2VhM3BxVzgtTU5aVERVRXFBRFZYcXZTamVaSGY0ZUNxYU0?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwJBVV95cUxNa2tFNWpSTFh5STFoTEpCN2VKX19KdTBWSWhXdHlOMEpiYmpFWWdPdjRRc0YtRlFDcldSWFdpbTE5UTdpcS1fcFR0aTdrUEIzbS1HaGM2cVFFU1ZUTWpGQm1vV0xvU21BZXBvSnJ4TGZBZ3dJaldpclhmdXNsYm91YmtyZWdWTWZ5VzZqZnc0U1F4X1RUZHUxMlBaMVEzTGo0LVg0Mk1Gei1kV2JSQUdXdVRoNVcyakVfc2J5MlFQRDdFQThjWmx4TjlZeFA5U2phRVZXSFBzMXVLbWtvYUd3TjBMdjFoTlVUdEZUdGYzY2NRaW5lX3JELWxpc0hQYndjQ1FzY0RHWDY2SVU?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) Share Price, SCNI Stock News, SCNI Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTFAzQXg1STNLcFhFYko3djA2cEROUmQzTVdmVzZIX2ZRTTl6c1Z1WmdQWkU2dWE1VjVVY01yY2ptRG54R2hXeWpYSXhMdktiUHktYkhMWWVB?oc=5", "source_name": "Kalkine", "published_at": "2025-11-10T23:35:15+00:00", "published_display": "10 Nov 2025 23:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Forms CDMO Subsidiary in US", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbmo5S3QyMjBWcnRZMGlfS3ZRT1J5OVNrUTgtcFU1SE03NDRFNHVlRFRtRXFZVDJOM0Jjdm1ITWJuU1ozbl82SVpWSFBYQWRZeVJ6NVBTS3pZZGN5U091Nl9iODRWMnZqNl8wQnZXcXdfYkhNWXZYeTdDTHlua3dwMm1yN2RkTG9rd1pDV3FDdlVYbEp1UUNWMQ?oc=5", "source_name": "BioPharm International", "published_at": "2024-12-18T08:00:00+00:00", "published_display": "18 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI Stock Price and Chart \u2014 NASDAQ:SCNI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5Ya2NDeEZkNzFtbERJUEtoZ1pQVTdFak1VY2FtTHNiMTJFTlJFVU5Wc0l0MHVuajZZYm16Z213cXdfWlMxYjJWSFMyaVFaM083UVh0Tm44ZldGT3dG?oc=5", "source_name": "TradingView", "published_at": "2023-09-20T21:39:14+00:00", "published_display": "20 Sep 2023 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBmUjZxNENBMVZTUWFHSkY3MW5YVVFFTTg5Zk9IdEJEaEF0N2ZrcHlLTUdGMERkcnRpY3J6Z09BOE9HYXFYSExoRzBDdEdKaDcwM2NJcm1PNFc1QQ?oc=5", "source_name": "MarketBeat", "published_at": "2023-09-18T16:35:16+00:00", "published_display": "18 Sep 2023 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Scinai Immunotherapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAJBVV95cUxNM1oxazlvUUl4bkozRV8yUXVjX1lVcEwtLXFpRmdrZnRhU3U1QWZid0drdVZ0RkEtV0VNQy14Rmp3U1B1OHJ4VXpUZzg3M05vTnp3N3kxNTVLaXVfTkd3SWlpZS1kTnhNVTVscC1iREVnR3MtNzZrWXZta0QzWTFFSU1vZUZBVjJ2VWZ0NjluVTItRVY1WDVRUnJsOGZreUpKREFQOUxmQnpMeGR4allRTFd0aklySkpIeUpKbDVqQXVRVUFqR21vUUNvSmt1OUVmU1hycjBBbHl2X0ZxMlRiQ3lhMnFOemRNTlE2QWJmMm1VUEZ4NW9SMnpEdnk0NlpSd2FGVHA3b21NQ1A5aEVnMFQ4MWE5Y0tkM1NUbW56enZRMzBRVDh0OFFubDVyS3ZwVE5BUjJxZEhvd0JRWDMtclBxdFNQUlMt?oc=5", "source_name": "Moomoo", "published_at": "2026-07-18T07:06:54+00:00", "published_display": "18 Jul 2026 07:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LCK JNK 1 LLC takes 6.33% stake in Scinai Immunotherapeutics (SCNI)", "summary": "LCK JNK 1 LLC has reported a 6.33% passive stake in Scinai Immunotherapeutics (SCNI), holding 317,366 American Depository Shares (ADS). Each ADS represents 4,000 ordinary shares. The filing indicates LCK JNK 1 LLC holds sole voting and dispositive power over these shares, as deta", "url": "https://www.stocktitan.net/sec-filings/SCNI/schedule-13g-a-scinai-immunotherapeutics-ltd-amended-passive-investme-775947b5d66c.html", "source_name": "Stock Titan", "published_at": "2026-07-09T13:35:29", "published_display": "09 Jul 2026 13:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI - Scinai Immunotherapeutics Ltd ADR Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Scinai Immunotherapeutics Ltd ADR (SCNI), along with a comprehensive overview of its financial performance, key metrics, and market data. It covers various aspects such as market capitalization, income, sales, per-share ", "url": "https://finviz.com/stock?t=SCNI&ty=lf&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-05T07:40:38", "published_display": "05 Jul 2026 07:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI - Scinai Immunotherapeutics Ltd ADR Options", "summary": "This article provides detailed financial data and performance metrics for Scinai Immunotherapeutics Ltd ADR (SCNI). It includes key financial ratios, stock performance over various periods, insider ownership, institutional ownership, and volume data. The stock closed at $0.2408, ", "url": "https://finviz.com/stock?t=SCNI&ty=oc&p=d&b=1", "source_name": "Finviz", "published_at": "2026-07-04T19:42:02", "published_display": "04 Jul 2026 19:42", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Surges 7.68% as Speculative Interest Intensifies - Andrews Pitchfork", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPQlpHdFF2ZEdqX1hEdnRDS2lXMXAwSmttYnJQV2MycVNjMzIzSkZFNkc1bFg1Snp5MVRTcklpZmRxR3l4ajBNRkdYS1hlcnUzMWotUV8tU1lLbjI0aFZCUGNsb3F5WTR6MzFqZnpzWmRfNXdydEpUWHBJTzFkcmkxQ01YZ29uY29iblVBQmNuS2VQNFlvQkhHY05MdE9rSWxCZzE4Y0ZDMlVsZ0JuT3hqdDN4U3BZdkN1MGhHQ2Z3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T22:44:17+00:00", "published_display": "01 Jul 2026 22:44", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Daniel Stone, RK Stone Miami adjust SCNI holdings (SCNI) after warrant exercises", "summary": "Daniel Stone and RK Stone Miami, LLC have updated their holdings in Scinai Immunotherapeutics Ltd. (SCNI) following warrant exercises, as reported in an amended SCHEDULE 13G/A filing. The filing details increased sole voting power for both parties, with RK Stone Miami, LLC exerci", "url": "https://www.stocktitan.net/sec-filings/SCNI/schedule-13g-a-scinai-immunotherapeutics-ltd-amended-passive-investme-6b721a9e5942.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:40:06", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI)", "summary": "This article provides an overview of Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), including its stock market information, financial data, and analyst estimates. It highlights that users can explore reported financial data, compare actual results with estimates, and visualize fin", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:17", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Scinai Immunotherapeutics Ltd. \u2013 NASDAQ:SCNI", "summary": "This article provides the \"Price to sales forward\" financial metric for Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI). It appears to be a stub or an incomplete data entry, as the actual value and change for the metric are not displayed. The page lists various navigation and copyr", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:17", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Scinai Immunotherapeutics Ltd. \u2013 NASDAQ:SCNI", "summary": "This article provides financial information for Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data display page from TradingView, indicating no available trades and offering various market d", "url": "https://www.tradingview.com/symbols/NASDAQ-SCNI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T08:40:16", "published_display": "25 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Scinai Immunotherapeutics Ltd (SCNI), noting its current valuation score is 7.47, ranking it 215 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -0.08, which is significantly belo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T02:09:20", "published_display": "23 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Drops 9.5% as Shares Approach Key Support at $0.28 - Short Term Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQWG1QbVZoTVBVeENIeThVSWp2bVp6MHZIREhuY2xNY25CTG40Q3kza0haeFhSLWtlcktiU2lRb0JCclMxdWRXNGo2dFRTNkhZLWtrZmZRSTNsU1pWYUxzMEpiMVNGT2tDX3NtczJyeWg2SEVZajBaM25GV2lTR3gzYXUxS0JyWmJPal9Fa3FwWEI2UC04WS1IUy0weDQzeDFJTHBjS3hRRkxub0JwSXZtQnhXVVdfSTFpV0IxdUd3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd", "summary": "This article provides a company overview for Scinai Immunotherapeutics Ltd (SCNI), including its stock performance and market capitalization. It highlights that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The page also", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/revenue", "source_name": "TradingKey", "published_at": "2026-06-20T17:40:06", "published_display": "20 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Scinai Immunotherapeutics Ltd (SCNI), outlining its major shareholders and institutional holdings. It provides a breakdown of individual and corporate shareholders, their respective proportions, and historical data on institutiona", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/ownership", "source_name": "TradingKey", "published_at": "2026-06-20T16:40:06", "published_display": "20 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Scinai Immunotherapeutics Ltd's (SCNI) dividend history and stock split events. It notes that SCNI has distributed $0.00 in dividends over the past five years and lists several merger-type stock splits that occurred on May 6, 2024, and Novembe", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-20T15:40:06", "published_display": "20 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Shareholders Approve Board Slate, Equity Expansion and Executive Awards", "summary": "Scinai Immunotherapeutics shareholders approved the re-election of directors, an amendment to increase authorized ordinary shares for capital raising flexibility, and several executive and board compensation items. These approvals included amendments to CEO Amir Reichman's employ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/SCNI/pressreleases/2532223/scinai-immunotherapeutics-shareholders-approve-board-slate-equity-expansion-and-executive-awards/", "source_name": "The Globe and Mail", "published_at": "2026-06-20T15:10:35", "published_display": "20 Jun 2026 15:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) CEO receives 400,000,000-share RSU award", "summary": "Scinai Immunotherapeutics Ltd. CEO Amir Reichman was granted 400,000,000 Ordinary Shares as Restricted Share Units (RSUs) on June 16, 2026, at a price of $0.00 per share. These RSUs will vest in three equal annual installments, contingent upon his continued service. Following thi", "url": "https://www.stocktitan.net/sec-filings/SCNI/form-4-scinai-immunotherapeutics-ltd-insider-trading-activity-c89ae117de41.html", "source_name": "Stock Titan", "published_at": "2026-06-18T18:40:56", "published_display": "18 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) director awarded 120M Ordinary Share RSUs", "summary": "Scinai Immunotherapeutics director Mark Germain was awarded 120 million Ordinary Shares as Restricted Share Units (RSUs) on June 16, 2026. These RSUs were granted at no cash cost and will vest in three equal annual installments, contingent on his continued service. Following this", "url": "https://www.stocktitan.net/sec-filings/SCNI/form-4-scinai-immunotherapeutics-ltd-insider-trading-activity-e9b1c9269701.html", "source_name": "Stock Titan", "published_at": "2026-06-18T18:40:56", "published_display": "18 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Scinai Immunotherapeutics Ltd (SCNI), providing a financial score of 6.87, which ranks it 197th in the Biotechnology & Medical Research industry. It notes the company's stable financial status and high operating efficiency. However, t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:56", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Scinai Immunotherapeutics Ltd (SCNI), noting that no earnings forecast score is currently available for the company. It highlights that the biotechnology and medical research industry average is 8.13 for this score. The article also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:56", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (SCNI) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Scinai Immunotherapeutics Ltd (SCNI), highlighting its current score and changes. It lists top institutional shareholders and their recent activity, including shares held and percentage change. The data is cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scni/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T23:40:56", "published_display": "17 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) investors approve board, share hike, RSU grants", "summary": "Scinai Immunotherapeutics shareholders approved all proposals at their Annual Meeting on June 16, 2026. Key approvals included the re-election of directors, an amendment to increase the number of authorized ordinary shares, and several compensation-related items for CEO Amir Reic", "url": "https://www.stocktitan.net/sec-filings/SCNI/6-k-scinai-immunotherapeutics-ltd-current-report-foreign-issuer-a15e4672eab1.html", "source_name": "Stock Titan", "published_at": "2026-06-17T10:10:51", "published_display": "17 Jun 2026 10:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI SEC Filings - Scinai Immunotherapeutics Ltd. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Scinai Immunotherapeutics Ltd. (SCNI) SEC filings, including annual, quarterly, and current reports, along with insider trading forms. It highlights recent filings such as the denial of a Euro 12M grant for PC111 development, a new ", "url": "https://www.stocktitan.net/sec-filings/SCNI/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T23:40:56", "published_display": "16 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai (NASDAQ: SCNI) posts Q1 2026 profit on Recipharm Israel gain", "summary": "Scinai Immunotherapeutics (NASDAQ: SCNI) reported a net income of $3.6 million for Q1 2026, primarily driven by a $6.2 million non-cash bargain purchase gain from its acquisition of Recipharm Israel. Despite an operating loss of $2.5 million, the acquisition significantly strengt", "url": "https://www.stocktitan.net/sec-filings/SCNI/6-k-scinai-immunotherapeutics-ltd-current-report-foreign-issuer-00dbf42694e9.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:34", "published_display": "15 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives", "summary": "Scinai Immunotherapeutics Ltd. reported its financial results for the first quarter of 2026, highlighting the acquisition of Recipharm Israel which expanded its CDMO platform and manufacturing capabilities. The company also provided a corporate update, detailing advancements in n", "url": "https://www.prnewswire.com/il/news-releases/scinai-reports-first-quarter-2026-financial-results-and-provides-corporate-update-highlighting-expansion-of-cdmo-platform-and-advancement-of-strategic-growth-initiatives-302796684.html", "source_name": "PR Newswire", "published_at": "2026-06-14T19:09:41", "published_display": "14 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd. (SCNI) stock price, news, quote and history", "summary": "Scinai Immunotherapeutics Ltd. (SCNI) is a biopharmaceutical company specializing in the research and development of immune-mediated and inflammatory disease treatments, including an IL-17 NanoAb platform and PC111 for conditions like pemphigus. The company also provides contract", "url": "https://au.finance.yahoo.com/quote/SCNI/", "source_name": "Market source", "published_at": "2026-06-12T10:09:40", "published_display": "12 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]", "summary": "This document is classified as a 6-K report, which is a filing submitted by foreign private issuers to the U.S. Securities and Exchange Commission (SEC) under Rules 13a-16 and 15d-16. The content of the report is simply \"Document,\" indicating it is a placeholder or an external do", "url": "https://www.moomoo.com/news/notice/307487099/scinai-immunotherapeutics-6-k-report-of-foreign-private-issuer-rules", "source_name": "Moomoo", "published_at": "2026-06-12T09:10:26", "published_display": "12 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives", "summary": "Scinai reported its first quarter 2026 financial results, emphasizing the expansion of its CDMO platform and the advancement of strategic growth initiatives. The report likely details the company's financial performance and operational developments during the quarter, reflecting ", "url": "https://www.moomoo.com/news/post/71330980/press-release-scinai-reports-first-quarter-2026-financial-results-and", "source_name": "Moomoo", "published_at": "2026-06-11T10:09:40", "published_display": "11 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai reports Q1 2026 net income of $3.6 million", "summary": "Scinai Immunotherapeutics Ltd reported a net income of $3.6 million for Q1 2026, a significant turnaround from a $1.6 million net loss in the previous year. This improvement was largely due to a $6.2 million bargain purchase gain from the acquisition of Recipharm Israel, which al", "url": "https://scanx.trade/stock-market-news/companies/scinai-reports-q1-2026-net-income-of-3-6-million/42639352", "source_name": "scanx.trade", "published_at": "2026-06-10T12:39:22", "published_display": "10 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics reports Q1 2026 financial results", "summary": "Scinai Immunotherapeutics (NASDAQ:SCNI) reported a net profit of $3.6 million for Q1 2026, a significant turnaround from a loss in the prior year, primarily due to a $6.2 million non-cash bargain purchase gain from its Recipharm Israel acquisition. Despite this, total revenues de", "url": "https://grafa.com/en/news/united-states/scni-earnings-q1-2026", "source_name": "grafa.com", "published_at": "2026-06-10T12:10:00", "published_display": "10 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Q4 2023 Earnings: EPS Surpasses Estimates Amid Continued Development Progress - EPS Surprise History", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQaFRBaVZ1eGZ4ay1BRlNlOEdiNTdUWFROSkRKZWFBVGRPSkxRRW96Vi1Cb3RkRngtblpGOWdvWFlMWVRCU2pldEpIbHRwVmIwdUpqTXpFUXE0bEdrVDBkMndCNnpYVGlMeGdjclROUzFKVW0xSmVYX2pQSVBWWUN6bW9KYkZGWHdHQmxxWi1yZVIzcXE4OFZSNDVUby1VQ0ZSVjdyVlJ5cVVaVFQ2U2ljaGhrcjZrZWVUTDl5QnJ2WVR3Qlc2RU14RGZINm92WlhtM0NFOVpDemlDaUI4dmo3cUlydw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Declines 7.25%, Eyes Key Support at $0.43 - Ichimoku Kumo Twist", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNMUJ6bnlwU3lhaXQ5eFhMTGdJRHp2TWV5bmE1a2xoMzh6SU1TanlFZHlMOThoNXI2TVVzNVlZczYzVG1ETnBEdHI2MkszTkp4d0gzRkxyTXRkd3MxczBNeEU0MWdVQUIybE1mVnQxUzQ5QTgwUDRxaUx5TnRWcGF0cTRzS3dDWlNjZ085U29JMFQzdlU1ZjcxVHM5a0llRGVpZmZ3TGZHVG1hUUJZTFhDM1hR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scinai-biopharma-services-appoints-eilon-110000686.html", "source_name": "PR Newswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scinai-immunotherapeutics-lead-strategic-roundtable-113000591.html", "source_name": "PR Newswire", "published_at": "2026-05-15T11:30:00+00:00", "published_display": "15 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai raises $2.61M to expand drug manufacturing, fund programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPbVBUOW0wajJNQ1d0YW85VUNKaTNxYVNkeDFac0czWG9FSTdqcUdTVy04SksyeXhrQjNuMVZjXzJlWUpHOEVkQkxYclZLNWRUcGVaRFVDUmxIcGM4U0l5TW1FUzUtQ0F3dnpKcFg3bW13aE1ReklGX0t0X2tXRHlaV2lVamlZT1VPTzVOaGx1cms2WU02dVNnb0huNzhTRmVaZHhqLWM4aTg5RDREX0VGellyUjdEOUk0Zkhpc1B3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxObm9GSzhISjhoN0FGb2dIOURDTDF2Z1Z0UEFpVTZMU29qRzVicVdRNm1yV2tmSl9DOTVveWhETnhIcDZJTzZ6WjhHZHp3S1ZaYXBiTWttT0pLOTRGbDFGNjhmXzlaanhCMEl0NDVuSFlLbGw2OUc1R0U2WWcwTEg5LVljUS0tU0dCTUdGcC1EdzY1MDNRbzVzdFd3NjlqX243QkRmQXI5SThKemxfVG9rb3BkWmFHOG9Kd0VtWXdrT2RpZ3dWNlFzNWVmb3Y?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics jumps on $2.61M private placement financing | SCNI Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUVhMTlMtd1llNEhJSUdPSWs1WF9CTDNBdGhLNW9oZ2hweTRvREVWTFg5Vkp4TU1oZ0dSQkQ3dm1uYU1CN09JTkE5WXRzT01Jc091OWZ1SWFLSkRIcndtVGJpSHhIempPYVMzUHRuVnJpZ2dtVlhzOXprQXNUYTI2ZHAxSnRPdXhBdDRFQU1neWwwZjB1Y3N1MkRqTUttM0Y3TGNNWQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxOMXlxdUZTTHRmeEQ2TmIwSUtIRzRwVHpaWVdiTFBsSmxrV3hybEh0dTZ5VXNWUm9jenVnZkh1dVF4UGhZbWI5UmFhQmtlN2ZXNFd4VVByZ1BmM3RqWjlFeGdGeUtWNFdia0Qzei1qZXlVT3d5eko1bFcxRWdOeVd0X1ctZ0p6ZUpJTzIwbjFQa0hOeXZWWXJtZGp5TU5hZm9zX3VvSi1YSmR4cXIxOTdVaUZwU3hCd05lV01Wc2tkZHNMYVhOTkhQcjFmSzZGOHdOUEdNTGE2YU1WWnozcmF1QjRuVVhid2VhM3BxVzgtTU5aVERVRXFBRFZYcXZTamVaSGY0ZUNxYU0?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwJBVV95cUxNa2tFNWpSTFh5STFoTEpCN2VKX19KdTBWSWhXdHlOMEpiYmpFWWdPdjRRc0YtRlFDcldSWFdpbTE5UTdpcS1fcFR0aTdrUEIzbS1HaGM2cVFFU1ZUTWpGQm1vV0xvU21BZXBvSnJ4TGZBZ3dJaldpclhmdXNsYm91YmtyZWdWTWZ5VzZqZnc0U1F4X1RUZHUxMlBaMVEzTGo0LVg0Mk1Gei1kV2JSQUdXdVRoNVcyakVfc2J5MlFQRDdFQThjWmx4TjlZeFA5U2phRVZXSFBzMXVLbWtvYUd3TjBMdjFoTlVUdEZUdGYzY2NRaW5lX3JELWxpc0hQYndjQ1FzY0RHWDY2SVU?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) Share Price, SCNI Stock News, SCNI Share Price & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTFAzQXg1STNLcFhFYko3djA2cEROUmQzTVdmVzZIX2ZRTTl6c1Z1WmdQWkU2dWE1VjVVY01yY2ptRG54R2hXeWpYSXhMdktiUHktYkhMWWVB?oc=5", "source_name": "Kalkine", "published_at": "2025-11-10T23:35:15+00:00", "published_display": "10 Nov 2025 23:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics Forms CDMO Subsidiary in US", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbmo5S3QyMjBWcnRZMGlfS3ZRT1J5OVNrUTgtcFU1SE03NDRFNHVlRFRtRXFZVDJOM0Jjdm1ITWJuU1ozbl82SVpWSFBYQWRZeVJ6NVBTS3pZZGN5U091Nl9iODRWMnZqNl8wQnZXcXdfYkhNWXZYeTdDTHlua3dwMm1yN2RkTG9rd1pDV3FDdlVYbEp1UUNWMQ?oc=5", "source_name": "BioPharm International", "published_at": "2024-12-18T08:00:00+00:00", "published_display": "18 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCNI Stock Price and Chart \u2014 NASDAQ:SCNI", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5Ya2NDeEZkNzFtbERJUEtoZ1pQVTdFak1VY2FtTHNiMTJFTlJFVU5Wc0l0MHVuajZZYm16Z213cXdfWlMxYjJWSFMyaVFaM083UVh0Tm44ZldGT3dG?oc=5", "source_name": "TradingView", "published_at": "2023-09-20T21:39:14+00:00", "published_display": "20 Sep 2023 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBmUjZxNENBMVZTUWFHSkY3MW5YVVFFTTg5Zk9IdEJEaEF0N2ZrcHlLTUdGMERkcnRpY3J6Z09BOE9HYXFYSExoRzBDdEdKaDcwM2NJcm1PNFc1QQ?oc=5", "source_name": "MarketBeat", "published_at": "2023-09-18T16:35:16+00:00", "published_display": "18 Sep 2023 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 50, "sentiment_summary": {"positive": 10, "negative": 5, "neutral": 35, "score": 52, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 0.25, "latest_week": "2026-07-17", "one_week_move": -0.4, "four_week_move": -22.3, "twelve_week_move": -66.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.998749, "market_dynamics_buy_signal": false, "relative_strength": -76.447277, "fair_value_gap": -93.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.0586, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, -22.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "PR Newswire", "count": 6}, {"label": "dars.gov.et", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 8}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.4% over one week, -22.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Scinai Immunotherapeutics Company Profile & Introduction"}], "updated_at": "2026-07-18T16:30:18.141156+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}